ArticleOpen forum infectious diseases2026
Comparison of Human Metapneumovirus- and Respiratory Syncytial Virus-Associated Health Burden in Adults With Chronic Underlying Health Conditions: A Global Systematic Review and Meta-analysis.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to systematically compare globally the health burden associated with human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) respiratory tract infections in adults with chronic illnesses. Methods: We searched MEDLINE, EMBASE, Global Health, CINAHL, Web of Science, and Global Index Medicus on 18 August 2025 and 12 January 2026. We included observational and interventional studies conducted from 2001 onwards, reporting laboratory-confirmed hMPV and RSV infections in adults with chronic illnesses. Quality assessment was conducted using the Joanna Briggs Institute critical appraisal tools. We developed an overall test positivity estimate, using a generalized linear mixed-effects model with a binomial distribution and logit link, including a study-level random intercept and fixed effects for virus, setting, and their interaction. Predicted probabilities and population-average odds ratios (ORs) comparing RSV and hMPV were calculated. Incidence and disease severity outcomes were synthesized narratively due to heterogeneous and limited data. The protocol was registered on Open Science Framework (doi:10.17605/OSF.IO/EPB3X). Results: Fifty studies, reporting on hMPV and RSV test positivity (n = 44; 29,603 laboratory tests), incidence (n = 3), and disease severity outcomes (n = 7), were included. The OR of RSV test positivity versus hMPV in adults with at least 1 chronic illness was 1.88 (95% confidence interval: 1.61-2.19) in inpatient settings and 1.65 (1.43-1.91) across all settings in studies relying on annual data. Significant differences in RSV versus hMPV test positivity were found for chronic respiratory disease (annual and seasonal analyses), cardiovascular (seasonal), immunocompromised (annual), and hematologic (annual) conditions but not among solid organ transplant recipients (annual). Incidence and severity data demonstrated inconsistent patterns. Conclusions: Respiratory syncytial virus occurs more frequently than hMPV in adults with chronic illnesses. However, evidence gaps remain regarding comparative disease severity and data from low- and middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.